Awakn Life Sciences ( (TSE:AWKN) ) has provided an update.
Awakn Life Sciences has entered into an arrangement agreement with Solvonis Therapeutics, under which Solvonis will acquire all outstanding shares and units of Awakn. This transaction offers Awakn shareholders a significant premium on their shares and provides the company with access to the London Stock Exchange’s capital markets, potentially enhancing its growth and development opportunities.
More about Awakn Life Sciences
Awakn Life Sciences is a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders.
YTD Price Performance: 8.33%
Average Trading Volume: 37,911
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.76M
For detailed information about AWKN stock, go to TipRanks’ Stock Analysis page.